Table 3.

Subgroup analysis of RPA-generated risk stratification and IC+CCRT vs. CCRT with adjustment.

Variables	High risk vs. low risk		IC+CCRT vs. CCRT
			High risk		Low risk
	HR (90% CI)	P	aHRa (90% CI)	P	aHRa (90% CI)	P
Age, year
18–37	3.30 (1.43–7.64)	0.005	0.94 (0.30–3.01)	0.922	0.81 (0.22–3.01)	0.749
38–44	2.81 (1.53–5.18)	0.001	0.47 (0.21–1.04)	0.061	0.83 (0.31–2.18)	0.700
45–52	3.29 (1.61–6.71)	0.001	0.89 (0.34–2.34)	0.810	1.11 (0.36–3.39)	0.862
≥53	1.71 (1.07–2.73)	0.024	0.34 (0.16–0.73)	0.006	0.50 (0.23–1.07)	0.076
Albumin, g/L
<40.0	2.30 (1.02–5.18)	0.044	0.42 (0.14–1.25)	0.117	0.56 (0.13–2.39)	0.433
≥40.0	2.40 (1.73–3.33)	<0.001	0.67 (0.43–1.06)	0.085	0.78 (0.47–1.28)	0.320
LDH, U/L
≤250	2.33 (1.68–3.25)	<0.001	0.44 (0.27–0.71)	0.001	0.79 (0.48–1.29)	0.343
>250	2.43 (1.09–5.46)	0.026	2.61 (0.75–9.08)	0.132	0.13 (0.02–1.02)	0.057
T category
T3	2.51 (1.80–3.49)	<0.001	0.53 (0.34–0.83)	0.005	0.72 (0.43–1.21)	0.212
T4	2.16 (0.95–4.91)	0.065	1.80 (0.38–8.46)	0.456	0.60 (0.18–2.07)	0.422
N category
N0	5.37 (2.85–10.11)	<0.001	1.42 (0.58–3.48)	0.444	0.74 (0.27–2.06)	0.567
N1	2.02 (1.43–2.85)	<0.001	0.48 (0.30–0.79)	0.003	0.65 (0.38–1.12)	0.119
IC regimen
TPF	2.34 (1.63–3.35)	<0.001	0.38 (0.20–0.72)	0.003	0.62 (0.32–1.21)	0.159
PF	3.15 (2.19–4.54)	<0.001	1.16 (0.66–2.02)	0.613	0.37 (0.11–1.18)	0.092
TP	2.28 (1.60–3.24)	<0.001	0.58 (0.32–1.06)	0.078	1.10 (0.60–2.02)	0.757

RPA, recursive partitioning analysis; CCRT, concurrent radiochemotherapy; IC, induction chemotherapy; HR, hazard ratio; aHR, adjusted hazard ratio; LDH, lactate dehydrogenase; TPF, docetaxel–cisplatin−5-fluorouracil; PF, cisplatin−5-fluorouracil; TP, docetaxel–cisplatin.

^aaHR was adjusted for age, albumin, LDH, T category, N category, and IC regimen, except for the variable that is being analyzed.